UH Cancer Center NCORP seated on Alliance for Clinical Trials in Oncology’s Board of Directors
February 7, 2020
As a top 40 accruer of clinical trials among The Alliance for Clinical Trials in Oncology institutions, the University of Hawaiʻi Cancer Center as a Hawaii Minority Underserved NCI Community Oncology Research Program (NCORP) site has been seated on the Alliance Board of Directors for a three-year term of 2020-2022.
The NCI Community Oncology Research Program (NCORP) at the University of Hawaiʻi Cancer Center is designed to provide the best cancer clinical trials to and increase participation of Hawaiʻi’s minority, rural, and underserved patient populations.
Out of 46 NCORP granted sites the UH Cancer Center is one of only 14 designated as an NCORP Minority/Underserved Community Site where the patient population is comprised of at least 30 percent racial/ethnic minorities or rural residents. The Center has been a member of this program (and its earlier version called the Minority-Based Community Clinical Oncology Program) since 1994.
As the Hawaiʻi Underserved Minority NCORP Principal Investigator, Jeffrey Berenberg, MD, will fulfill the duties of the position throughout the term. The Board of Directors will guide efforts to reduce the burden of cancer through the collaboration of experts who are committed to finding new ways to prevent and treat the disease.
